LabCorp and Quest Diagnostics this week disclosed unauthorized activity on the web payment page of the companies’ billing collections service provider.
The global oncology market last year set several records, though the industry continues to struggle with long development timelines, which in 2018 averaged 10.5 years from patent filing to regulatory approval and launch, according to a recent Iqvia report.
Atomwise signs a multi-year agreement with Eli Lilly and Company through which it will apply its patented artificial intelligence technology to support Lilly’s preclinical drug discovery efforts.
Broader clinical trial eligibility criteria would double patient numbers in lung cancer studies, according to a new report from ASCO, which has been leading efforts to expand access to oncology clinical trials.
Gilead and HitGen have signed a drug discovery collaboration – one of several recently announced agreements as HitGen sees increased demand for its technology, says CSO.
The US FDA approves Merck’s application to expand the label of Zerbaxa for the treatment of hospital-acquired infections to address ‘global challenge’ of AMR.
The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.
The online marketplace for outsourced R&D services Scientist.com partners with 5AM Ventures to help researchers save time and money – as the industry is "caught between a rock and a hard place," says CEO.
Lonza announces that its Specialty Ingredients business will operate independently by ‘mid-2020’ and will cut away approximately 130 roles at the same time.
This month’s roundup includes the first CFO for CytoReason, a new CEO at Certara and Factory-CRO, as well as an expanded leadership team at BioDuro, among other people on the move in May.
Parexel today unveiled its Oncology Center of Excellence as well as a new “early advisory service” focused on study design, regulatory strategy, and market access.
Risk-based monitoring should be described as a “best practice,” says ACRO, which recently released a survey that found the majority of new trial starts in 2018 employed some form of RBM.
PPD’s Evidera business unit is set to acquire Medimix International, a global technology company with a real-world evidence service offering that includes access to patient-level data, data analytics, and visualization capabilities.
EMA assembles pharmaceutical developers to strengthen antimicrobial pipelines while, in the meantime, a study found the world’s rivers dangerously contaminated.
Last year saw heightened market volatility, marked by international trade disputes, regulatory unrest, and a general feeling of uncertainty – but 2019 is off to a strong start with several multi-billion dollar deals.
Translational research faces new challenges – and opportunities – with the rapid growth in precision medicine and new drug modalities, as the industry looks to quickly bring new treatments to patients.
Vetter’s German sites will be supplied with only CO2 neutral energy from renewable energy sources as the company continues to work towards greater sustainability.
Although the industry may not be among the ‘frontrunners’, Novo Nordisk is seeing the benefits when it comes to recruitment and developing mutually beneficial partnerships, says director.
Clinical research in England is growing at a record-setting pace with support from a recent £20.5bn investment to transform service delivery – as the NHS looks to conduct more studies in primary care settings.
SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.
US FDA grants approval for Novartis’ Piqray to be used as combination treatment for advanced or metastatic breast cancer, a potential blockbuster drug.
Concerto HealthAI launches model to predict survival rates in lung cancer patients in an aim to garner disease insights that could improve enrollment criteria.
Mallinckrodt states that its specialty branded portfolio will be named Sonorant Therapeutics and, in a U-turn, this side of the business will take Amitiza with it.
Icon acquires a majority shareholding in MeDiNova Research, a UK-headquartered site network with operations across the EMEA region – and access to more than 5m potential study patients.
Heritage announces a recall of lots of amikacin sulfate injection and prochlorperazine edisylate injection, due to evidence of selected products being non-sterile.
Scancell and Cancer Research UK use nanodelivery technology to activate the body’s immune system, boosting its ability to target and destroy cancer cells.
Navitas has acquired KAI Research to expand its trial site footprint in North America and Africa as well as bolster its ability to manage clinical trials in a number of research areas.
Verily is aligning itself with big names in pharma to bolster its Project Baseline, designed to use digital sources to promote patient-centered clinical research programs.
Social, cultural, and financial barriers pose a challenge in enrollment for oncology clinical trials, but USC investigator believes mitigating barriers to diversify research may provide comprehensive data.
Artificial intelligence tools will allow the pharmaceutical companies to make predictions about diseases more effectively than before, says ImaginAB’s CEO.
BBK Holdings, parent company of BBK Worldwide, has established BBK Patient Experience Limited to support patient data protection in clinical trials and add to its footprint in the EU.
Kazia therapeutics is collaborating with the Alliance for Clinical Trials in Oncology Foundation to launch a Phase II study to investigate its brain cancer therapies targeted at tumors’ genetic profile.
Marken executive says there is no such thing as a perfect clinical trial supply chain but with strategic planning and innovations there are opportunities to better serve the research industry.